First Horizon Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

First Horizon Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$144	Hold	17	–	–	﹤0.01%	2296
2025 Q1	$137	Hold	17	–	–	﹤0.01%	2285
2024 Q4	$153	Hold	17	–	–	﹤0.01%	2252
2024 Q3	$125	Hold	17	–	–	﹤0.01%	2291
2024 Q2	$97	Hold	17	–	–	﹤0.01%	2266
2024 Q1	$85	Hold	17	–	–	﹤0.01%	2275
2023 Q4	$153	Hold	17	–	–	﹤0.01%	2345
2023 Q3	$132	Hold	17	–	–	﹤0.01%	2367
2023 Q2	$165	Hold	17	–	–	﹤0.01%	2424
2023 Q1	$186	Hold	17	–	–	﹤0.01%	2437
2022 Q4	$73	Sell	17 -135	-89%	-$783	﹤0.01%	2437
2022 Q3	$1K	Hold	152	–	–	﹤0.01%	2082
2022 Q2	$1K	Sell	152 -13	-8%	-$145	﹤0.01%	2177
2022 Q1	$2K	Sell	165 -535	-76%	-$8.27K	﹤0.01%	1425
2021 Q4	$16K	Hold	700	–	–	﹤0.01%	1346
2021 Q3	$14K	Buy	700 +493	+238%	+$7.82K	﹤0.01%	1393
2021 Q2	$2K	Buy	207 +86	+71%	+$1.1K	﹤0.01%	1731
2021 Q1	$1K	Buy	+121	New	+$1.76K	﹤0.01%	1741

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Horizon Advisors's AUPH Position: Q2 2025 in Review

First Horizon Advisors held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2025 at 17 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

First Horizon Advisors first reported a position in AUPH in Q1 2021 and has held it in 18 quarters since. The position peaked at $16K in Q4 2021. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

First Horizon Advisors held 17 shares of Aurinia Pharmaceuticals worth $144 as of Q2 2025.
First Horizon Advisors left its Aurinia Pharmaceuticals share count unchanged in Q2 2025.
Aurinia Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #2296 holding.
First Horizon Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
First Horizon Advisors's Aurinia Pharmaceuticals position peaked at $16K in Q4 2021.
219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.